Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 4, 2010, Pages 359-366

  Hiligsmann, Mickaël ^a   Vanoverberghe, Marie ^a   Neuprez, Audrey ^a   Bruyère, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

cost effectiveness; osteoporosis; strontium ranelate; treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE;

BELGIUM; BONE DENSITY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; ECONOMIC EVALUATION; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HEALTH ECONOMICS; HIP FRACTURE; HUMAN; NAUSEA; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SWEDEN; SYSTEMATIC REVIEW; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; HUMANS; MALE; MODELS, ECONOMIC; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; PATIENT SELECTION; RISK ASSESSMENT; SEX FACTORS; THIOPHENES; TREATMENT OUTCOME;

EID: 77955799402     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.53     Document Type: Review

References (46)

1. Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43, 991-994 (2008).
2. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos. Int. 11, 669-674 (2000).
3. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos. Int. 7, 407-413 (1997).
4. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399-428 (2008).
5. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459-468 (2004). (Pubitemid 38133766)
6. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 58, 1687-1695 (2008).
7. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90, 2816-2822 (2005).
8. Seeman E, Devogelaer JP, Lorenc R, et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J. Bone Miner. Res. 23, 433-438 (2008).
9. Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45, 1059-1064 (2009).
10. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res. 8, 607-615 (1993).
11. Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv. Ther. 25, 1235-1256 (2008).
12. Jonville-Bera AP, Crickx B, Aaron L, Hartingh I, Autret-Leca E. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy 64, 658-659 (2009).
13. Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos. Int. 19, 1811-1812 (2008).
14. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos. Int. 21, 723-732 (2010).
15. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY. Development and validation of a Markov Microsimulation Model for the economic evaluation of treatments in osteoporosis. Value Health 12, 687-696 (2009).
16. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis -a review of the literature and a reference model. Osteoporos. Int. 18, 9-23 (2007).
17. Borgstrom F, Jonsson B, Strom O, Kanis JA. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos. Int. 17, 1781-1793 (2006).
18. Borgstrom F, Strom O, Coelho J, et al. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos. Int. 21, 339-349 (2010).
19. Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46, 440-446 (2010).
20. Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos. Int. 21, 157-165 (2010).
21. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol. Assess. 11, 1-134 (2007).
22. Seeman E, Boonen S, Borgstrom F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 46, 1038-1042 (2010).
23. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making 13, 322-338 (1993).
24. Briggs A, Sculpher M, Claxton K. Modelling Methods for Health Economic Evaluation. Oxford University Press, NY, USA (2006).
25. Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. University Press, Cambridge, UK (2001).
26. Vanness DJ, Tosteson AN, Gabriel SE, Melton LJ 3rd. The need for microsimulation to evaluate osteoporosis interventions. Osteoporos. Int. 16, 353-358 (2005).
27. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos. Int. 20, 1663-1673 (2009).
28. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis -a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060-2066 (2002).
29. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos. Int. 13, 925-931 (2002).
30. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif. Tissue Int. 86, 202-210 (2010).
31. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 25, 913-933 (2007).
32. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos. Int. 17, 29-40 (2006).
33. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23, 570-578 (2002).
34. Borgstrom F, Kanis JA. Health economics of osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab. 22, 885-900 (2008).
35. Adachi JD, Kennedy CC, Papaioannou A, Ioannidis G, Leslie WD, Walker V. Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? Osteoporos. Int. 20, 1785-1793 (2009).
36. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. 19, 811-818 (2008).
37. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 17, 1645-1652 (2006).
38. Hiligsmann M, Rabenda V, Bruyre O, Reginster J. The clinical and economic burden of non-adherence with osteoporosis medications. Health Policy 97, 170-176 (2010).
39. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann. Rheum. Dis. 58(Suppl. 1), I82-I85 (1999).
40. Rabenda V, Reginster JY. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos. Int. DOI: 10.1007/s00198-009-1155-z (2010) (Epub Ahead of Print).
41. Breart G, Jakob FJ, Palacios S, et al. New interim analysis of a prospective observational cohort study of patients treated with strontium ranelate. Osteoporos. Int. 21(Suppl. 1), S166 (2010).
42. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across juridictions: ISPOR good research practices task force report. Value Health 12, 409-418 (2009).
43. Roux C, Fechtenbaum J, Kolta S, Isaia G, Cannata Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann. Rheum. Dis. 67, 1736-1738 (2008).
44. Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 28, 295-306 (2010).
45. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. A review of comments submitted by consultees on the economic model. Report by the Decision Support Unit. 14 August 2009 www.cost-effectiveness.org. uk/guidance/ index.jsp?action=download&o=46475
46. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Final appraisal determination. November 2009 www.cost-effectiveness.org. uk/guidance/ index.jsp?action=download&o=46463